Posts tagged Dr. Marc Rubin
Titan Pharma in talks with Braeburn about future of Probuphine partnership

Titan Pharmaceuticals (NASDAQ:TTNP) is in discussions with Braeburn Pharmaceuticals about their partnership for the development and commercialization of Probuphine, the first six-month maintenance treatment of opioid dependence. 

Read More
Titan Pharma adds two members to BOD

Titan Pharmaceuticals (NASDAQ:TTNP), in a move to boost its product development and commercialization experience in the U.S., Europe and Asia, named Scott Smith and Dr. Rajinder Kumar to its board.

Read More
Galectin appoints Dr. Marc Rubin as chairman

Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director.

Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of pharmaceuticals. He has been serving as lead independent director of Galectin.

Read More